Drugmaker Hikma Pharmaceuticals said trading in its generics unit was below its expectations due to slower-than-anticipated growth in the sales of its gout drug and cut its full-year revenue forecast for the unit.

Hikma now expects revenue in the generics business to be $150 million, down from its earlier range of $175 million to $200 million.

The Jordanian company, which makes and markets branded and non-branded generic and injectable drugs, also said it expected 2015 adjusted operating margins for the unit to be in the high twenties. - Reuters